timwest
Long

ACAD low risk long entry

BATS:ACAD   ACADIA PHARMACEUTICALS INC
1262 17 2
Volume and price patterns in ACAD             are giving me a reason to enter the market here.

ACAD             is trending strongly on a longer term basis. Price momentum on a quarterly basis is solid and it is retesting the breakout level after a tough week in the overall market last week. The advance by ACAD             from 2.30 to over 3.00 was on a solid increase in volume , indicating strong, new shareholder interest and long term support. The recent slide from 3.00 back to 2.20 was on lighter volume , indicating a "wait-and-see" attitude from the new shareholders.

I view $1.80-$1.90 as the stop loss area, which is a wide stop, but I feel it is necessary on a stock that can move 10% or 20 cents in a day.

Thanks to TradingView publisher @LiljaCat for pointing out the chart originally or else I wouldn't have wandered into such a new, low-priced stock .
Subscribe to my indicator package KEY HIDDEN LEVELS $20/mo or a discount for a year and join in the trading room KEY HIDDEN LEVELS here at TradingView.com
I bought ACAD @ 1.79 back in August. Just was waiting for phase 3 clinical test results schedule sometime for November. Pure speculation trade here for me .
Reply
Just waiting*
Reply
Ok. Thanks.
Reply
Do you have a link to the information surrounding the tests?
Reply
timwest PRO frankserravalli
I don't.
Reply
Algokid PRO frankserravalli
please see Seekingalpha.com. They many good articles about the stock and current testing
Reply
Thanks!
Reply
frankserravalli frankserravalli
For those interested:
Seekingalpha.com:

September 20 Acadia Pharmaceuticals (ACAD +13.2%) pushes to a new 52-week high today on the back of a Seeking Alpha article touting the potential of it's experimental anti-psychotic drug pimavanserin. On September 5, ACAD announced the completion of patient enrollment in a phase III study of the drug for treating Parkinson's disease psychosis. If approved, it will be the first antipsychotic drug to receive such approval, and will likely be immediately embraced, and extensively prescribed.

Further Reading available at: http://seekingalpha.com/news-article/4029481-acadia-pharmaceuticals-announces-completion-of-enrollment-in-phase-iii-pimavanserin-trial-in-parkinsons-disease-psychosis
Reply
Interesting chart, what about waiting until it breaks ~2.30 again with 2.30 as stop, or buy around 1.95-2.05 and stop out at 1.85?
Reply
timwest PRO marginofdoubt
What did you decide to do? The stock is tracing out the shaded projection pretty closely so far.
Reply
Nice action today to the upside :-)
Reply
admin PRO timwest
Bullseye!
Reply
wow.. nice call
Reply
timwest PRO QuantitativeExhaustion
It's nice to see a big move on a technical+fundamental idea. Nice team-work by everyone on this one! This is what TradingView is all about for me. Thanks TradingView.
Reply
Great Job Tim....Guess the result from the tests were good. :)
Reply
Ideas Scripts Chart
United States
United Kingdom
India
España
France
Italia
Polska
Brasil
Россия
Türkiye
Indonesia
日本
한국
Home Stock Screener Forex Signal Finder Economic Calendar How It Works Chart Features House Rules Moderators For the WEB Widgets Stock Charting Library Priority Support Feature Request Blog & News FAQ Help & Wiki Twitter
Private Messages Chat Ideas Published Followers Following Priority Support Public Profile Profile Settings Account and Billing Sign Out